Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines. (Q38079159)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Roman Pallares

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Adoracion Navarro-Torne

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

1 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

Current infectious disease reports

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

184-190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381547%20AND%20SRC:MED&resulttype=core&format=json

The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Epidemiology and etiology of childhood pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

The burden of community-acquired pneumonia in seniors: results of a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Epidemiological differences among pneumococcal serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Impact of the pneumococcal conjugate vaccine on otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Pediatric parapneumonic empyema, Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Bacterial causes of empyema in children, Australia, 2007-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Clinical and economic burden of pneumococcal disease in older US adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Review on the immunogenicity and safety of PCV-13 in infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Impact of pneumococcal conjugate vaccination on otitis media: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Nasopharyngeal bacterial interactions in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Nasal carriage of Streptococcus pneumoniae serotypes and Staphylococcus aureus in Streptococcus pneumoniae-vaccinated and non-vaccinated young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Respiratory viral and pneumococcal coinfection of the respiratory tract: implications of pneumococcal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Continued control of pneumococcal disease in the UK - the impact of vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

A review of the effect of immunization programs on antimicrobial utilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Streptococcus pneumoniae serotype 15A in psychiatric unit, Rhode Island, USA, 2010-2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-013-0326-4

Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines

21 January 2018

1 reference

12 December 2020

Emergence of pneumococcal 19A empyema in UK children

1 reference

12 December 2020

New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine

1 reference

12 December 2020

Viral Coinfection in Children Less Than Five Years Old With Invasive Pneumococcal Disease

1 reference

12 December 2020

Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods

1 reference

12 December 2020

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety

1 reference

12 December 2020

Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges

1 reference

12 December 2020

Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults

1 reference

12 December 2020

Update: pneumococcal polysaccharide vaccine usage--United States

1 reference

12 December 2020

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

1 reference

12 December 2020

Emergence of Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes in the Era of 7-Valent Conjugate Vaccine

1 reference

12 December 2020

Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain

1 reference

12 December 2020

Surveillance of certain health behaviors and conditions among states and selected local areas - Behavioral Risk Factor Surveillance System, United States, 2007.

1 reference

12 December 2020

Pneumococcal vaccines WHO position paper - 2012 - recommendations

1 reference

12 December 2020